We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+10.34%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$5.32B
AUM Growth
+$623M
(+13%)
Cap. Flow
+$473M
Cap. Flow
% of AUM
8.88%
Top 10 Holdings %
Top 10 Hldgs %
31.02%
Holding
1,563
New
308
Increased
332
Reduced
859
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Equinix
EQIX
|
+$43.7M |
| 2 |
American Tower
AMT
|
+$34.7M |
| 3 |
Crown Castle
CCI
|
+$21.3M |
| 4 |
CD
Chindata Group Holdings Limited American Depositary Shares
CD
|
+$19.1M |
| 5 |
CONE
CyrusOne Inc Common Stock
CONE
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$80.9M |
| 2 |
Microsoft
MSFT
|
+$63.9M |
| 3 |
Amazon
AMZN
|
+$61.8M |
| 4 |
Meta Platforms (Facebook)
META
|
+$26.4M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$24.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 18.33% |
| 2 | Technology | 16.44% |
| 3 | Consumer Discretionary | 8.8% |
| 4 | Healthcare | 7.69% |
| 5 | Communication Services | 7.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ICPT
1226
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $106K | ﹤0.01% |
4,303
+2,906
| +208% | +$96.3K |
|
1227
Kura Oncology
KURA
$826M
| $104K | ﹤0.01% |
3,176
+1,804
| +131% | +$63.4K |
|
1228
Heron Therapeutics
HRTX
$92M
| $102K | ﹤0.01% |
4,800
+794
| +20% | +$13.8K |
|
1229
Pembina Pipeline
PBA
$29B
| $102K | ﹤0.01% |
+4,329
| New | +$102K |
|
|
VXRT
1230
DELISTED
Vaxart
VXRT
| $102K | ﹤0.01% |
+17,786
| New | +$113K |
|
|
KRTX
1231
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $101K | ﹤0.01% |
990
+58
| +6% | +$5.37K |
|
|
BELFB
1232
Bel Fuse Inc Class B
BELFB
$3.57B
| $100K | ﹤0.01% |
6,644
+2,260
| +52% | +$30.4K |
|
|
VG
1233
DELISTED
Vonage Holdings Corporation
VG
| $99K | ﹤0.01% |
7,654
-1,458
| -16% | -$17.7K |
|
1234
WIX.com
WIX
$2.45B
| $98K | ﹤0.01% |
+394
| New | +$104K |
|
|
NVTA
1235
DELISTED
Invitae Corporation
NVTA
| $97K | ﹤0.01% |
2,330
-4,170
| -64% | -$199K |
|
|
VISN
1236
Vistance Networks Inc
VISN
$2.67B
| $96K | ﹤0.01% |
7,137
-152,673
| -96% | -$1.68M |
|
1237
Cardiff Oncology
CRDF
$63.6M
| $96K | ﹤0.01% |
+5,362
| New | +$94.2K |
|
|
SWTX
1238
DELISTED
SpringWorks Therapeutics
SWTX
| $95K | ﹤0.01% |
+1,310
| New | +$84.3K |
|
1239
Box
BOX
$4.36B
| $93K | ﹤0.01% |
5,125
-244
| -5% | -$4.25K |
|
1240
Replimune Group
REPL
$449M
| $92K | ﹤0.01% |
+2,404
| New | +$100K |
|
|
LKFT
1241
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
| $91K | ﹤0.01% |
922
+464
| +101% | +$56.7K |
|
1242
Revolution Medicines
RVMD
$39.1B
| $90K | ﹤0.01% |
+2,272
| New | +$89.8K |
|
1243
Coca-Cola Europacific Partners
CCEP
$49.2B
| $88K | ﹤0.01% |
+1,761
| New | +$74.4K |
|
1244
Teva Pharmaceuticals
TEVA
$36.9B
| $87K | ﹤0.01% |
9,031
-2,024
| -18% | -$19.4K |
|
1245
Ryanair
RYAAY
$31B
| $86K | ﹤0.01% |
1,963
-385
| -16% | -$15.1K |
|
|
DVAX
1246
DELISTED
Dynavax Technologies
DVAX
| $84K | ﹤0.01% |
18,775
+12,306
| +190% | +$55.7K |
|
1247
Vericel Corp
VCEL
$2.39B
| $83K | ﹤0.01% |
2,686
-924
| -26% | -$22K |
|
1248
Regenxbio
RGNX
$615M
| $79K | ﹤0.01% |
1,734
-612
| -26% | -$21.4K |
|
|
IGMS
1249
DELISTED
IGM Biosciences
IGMS
| $78K | ﹤0.01% |
884
+529
| +149% | +$37.2K |
|
1250
uniQure
QURE
$2.52B
| $75K | ﹤0.01% |
+2,072
| New | +$87.4K |
|
Similar funds
SAM
Pacer Advisors's Q4 2020 Portfolio in Review
As of Q4 2020, Pacer Advisors held 1,563 positions worth $5.32B, up 13% from $4.7B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Pacer Advisors deployed $473M of net new capital in Q4 2020, opening 308 new positions and adding to 332 existing holdings. Its largest new stake was Chindata Group Holdings Limited American Depositary Shares: 1,166,530 shares worth $27.9M.
By sector, the portfolio is most concentrated in Real Estate at 18% of assets, up from 17% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $80.9M trimmed.
- Pacer Advisors's largest Q4 2020 buy was Chindata Group Holdings Limited American Depositary Shares: 1,166,530 shares worth $27.9M.
- Pacer Advisors added most to Equinix in Q4 2020, an estimated $43.7M increase.
- Pacer Advisors's biggest Q4 2020 reduction was Apple, cutting an estimated $80.9M.
- Pacer Advisors fully exited INDUS Realty Trust, Inc. (MD) Common Stock in Q4 2020, selling an estimated $1.83M.
- Pacer Advisors's ten largest holdings make up 31% of its $5.32B portfolio in Q4 2020.
- Pacer Advisors opened 308 new positions and closed 60 in Q4 2020.
- Pacer Advisors's portfolio value rose 13% quarter-over-quarter to $5.32B.
Based on Pacer Advisors's 13F filing for Q4 2020, filed 20 Jan 2021.